IBBQ.US Invesco Nasdaq Biotechnology ETF
- Total assets
- 130M
- Expense ratio
- 0.18%
- Dividend yield
- 1.06%
- 1-year return
- +33.35%
- Holdings
- 245
- Since
- 2021
Fund data as reported by the issuer, updated Nov 15, 2026. Total assets are in the fund's base currency.
What does IBBQ.US invest in?
- Mostly US stocks (96.5%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (91.7%)
- Top 3 holdings: 25.6% of the fund
Asset allocation
- US stocks 96.5%
- Non-US stocks 4.9%
- Cash 0.1%
Top holdings
- Gilead Sciences Inc 9.13%
- Amgen Inc 8.35%
- Vertex Pharmaceuticals Inc 8.12%
- Regeneron Pharmaceuticals Inc 6.43%
- Moderna Inc 5.79%
Invesco Nasdaq Biotechnology ETF performance
Sharpe ratio 1.21- This year
- +30.41%
- 1 year
- +33.35%
- 3 years
- +26.50%
- 5 years
- +9.93%
Volatility 16.4% over 1 year and 16.0% over 3 years. Moderate, similar to a broad stock index.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
IBBQ.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About Invesco Nasdaq Biotechnology ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the index. Strictly in accordance with its guidelines and mandated procedures, Nasdaq compiles the underlying index, which is a modified market capitalization weighted index that is designed to measure the performance of securities listed on the Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical companies. The index may include securities of large-, …
Full fund profileInvesco Nasdaq Biotechnology ETF top holdings
48.5% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Gilead Sciences Inc GILD.US | Healthcare | United States | 9.13% |
| Amgen Inc AMGN.US | Healthcare | United States | 8.35% |
| Vertex Pharmaceuticals Inc VRTX.US | Healthcare | United States | 8.12% |
| Regeneron Pharmaceuticals Inc REGN.US | Healthcare | United States | 6.43% |
| Moderna Inc MRNA.US | Healthcare | United States | 5.79% |
| Biogen Inc BIIB.US | Healthcare | United States | 2.46% |
| Revolution Medicines Inc RVMD.US | Healthcare | United States | 2.34% |
| Illumina Inc ILMN.US | Healthcare | United States | 2.09% |
| Royalty Pharma Plc RPRX.US | Healthcare | United States | 2.02% |
| Roivant Sciences Ltd ROIV.US | Healthcare | United States | 1.80% |
The 10 largest of 245 holdings.
IBBQ.US sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
IBBQ.US regional exposure
- North America91.7%
- Europe Developed2.4%
- United Kingdom2.1%
- Asia Emerging0.1%
- Australasia0.0%
- Africa/Middle East0.0%
- Asia Developed0.0%
Share of the stocks in the fund.
Company size
Average market cap 29.5B- Mega cap0.6%
- Big cap33.6%
- Medium cap31.0%
- Small cap22.4%
- Micro cap10.5%
Invesco Nasdaq Biotechnology ETF fund profile
- Fund name
- Invesco Nasdaq Biotechnology ETF
- Ticker
- IBBQ.US
- Exchange
- USA Stocks
- Issuer
- Invesco
- Index tracked
- -
- Category
- Healthcare Equity
- Inception date
- Jun 11, 2021
- Trading currency
- USD
- Expense ratio
- 0.18%
- Annual turnover
- 0.1%
About Invesco Nasdaq Biotechnology ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the index. Strictly in accordance with its guidelines and mandated procedures, Nasdaq compiles the underlying index, which is a modified market capitalization weighted index that is designed to measure the performance of securities listed on the Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical companies. The index may include securities of large-, mid- and small-capitalization companies. The fund is non-diversified.